Werewolf Therapeutics, Inc. (CIK: 0001785530) EDGAR, Information, Filings... CompaniesBIO.Com

Werewolf Therapeutics, Inc.

Mailing address
200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN, Delaware, 02472
Phone
617-952-0555
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Werewolf Therapeutics, Inc. (CIK: 0001785530) is an American company incorporated in the state of Massachusetts. Head office is located at 200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN, Massachusetts, 02472. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Werewolf Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
EVNIN LUKE	0001134657	Jun-01-2022	director
Sherman Michael A.	0001509463	Jun-01-2022	director
Chatterjee Meeta	0001835388	Jun-01-2022	director
Karunatilake Chulani	0001867326	Jan-06-2022	officer: Chief Technology Officer
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	0001009258	Apr-29-2021	10 percent owner, other: Possible Member of 10% Group
Deerfield Mgmt L.P.	0001010823	Apr-29-2021	10 percent owner, other: Possible Member of 10% Group
GADICKE ANSBERT	0001134655	Apr-29-2021	10 percent owner
HBM Healthcare Investments (Cayman) Ltd.	0001232258	Apr-29-2021	10 percent owner
HICKLIN DANIEL J	0001260929	Apr-29-2021	director, 10 percent owner, officer: See Remarks
DEERFIELD PARTNERS, L.P.	0001301041	Apr-29-2021	10 percent owner, other: Possible Member of 10% Group
RA Capital Healthcare Fund LP	0001315082	Apr-29-2021	director, 10 percent owner
Arkin Moshe	0001321178	Apr-29-2021	10 percent owner
RA CAPITAL MANAGEMENT, L.P.	0001346824	Apr-29-2021	director, 10 percent owner
Flynn James E	0001352546	Apr-29-2021	10 percent owner, other: Possible Member of 10% Group
Kolchinsky Peter	0001384859	Apr-29-2021	director, 10 percent owner
Foley Todd	0001473930	Apr-29-2021	10 percent owner
SPHERA FUNDS MANAGEMENT LTD.	0001496201	Apr-29-2021	10 percent owner
Trost Timothy W.	0001571865	Apr-29-2021	officer: Chief Financial Officer
Sphera Global Healthcare Management LP	0001599854	Apr-29-2021	10 percent owner
Sphera Global Healthcare GP Ltd.	0001599855	Apr-29-2021	10 percent owner
MPM BioVentures 2014, L.P.	0001609492	Apr-29-2021	10 percent owner
MPM BioVentures 2014 (B), L.P.	0001609493	Apr-29-2021	10 percent owner
MPM Asset Management Investors BV2014 LLC	0001609495	Apr-29-2021	10 percent owner
Shah Rajeev M.	0001619841	Apr-29-2021	director, 10 percent owner
Longwood Fund III, L.P.	0001640546	Apr-29-2021	10 percent owner
UPMC	0001644244	Apr-29-2021	10 percent owner
Morrison Briggs	0001654430	Apr-29-2021	director
MPM Oncology Impact Management LP	0001687078	Apr-29-2021	10 percent owner
UBS Oncology Impact Fund L.P.	0001691428	Apr-29-2021	10 percent owner
MPM ONCOLOGY INNOVATIONS FUND LP	0001719960	Apr-29-2021	10 percent owner
MPM Oncology Impact Management GP LLC	0001721035	Apr-29-2021	10 percent owner
Oncology Impact Fund (Cayman) Management L.P.	0001721036	Apr-29-2021	10 percent owner
Longwood Fund III GP, LLC	0001762853	Apr-29-2021	10 percent owner
MPM BioVentures 2014 LLC	0001765021	Apr-29-2021	10 percent owner
MPM BioVentures 2014 GP LLC	0001765091	Apr-29-2021	10 percent owner
DiRocco Derek	0001792061	Apr-29-2021	director
Lazarus Alon	0001808244	Apr-29-2021	director, 10 percent owner
Leonard Reid	0001857795	Apr-29-2021	officer: Chief Operating Officer
Isaacs Randi	0001857797	Apr-29-2021	officer: Chief Medical Officer
Seidel-Dugan Cynthia	0001857799	Apr-29-2021	officer: Chief Scientific Officer
Asanuma Sakae	0001857822	Apr-29-2021	director, 10 percent owner
Lubman Ellen	0001857842	Apr-29-2021	officer: Chief Business Officer
MPM Oncology Innovations Fund GP LLC	0001857903	Apr-29-2021	10 percent owner
Taiho Ventures LLC	0001857906	Apr-29-2021	10 percent owner
Arkin Bio Ventures 2 L.P.	0001858705	Apr-29-2021	10 percent owner
Arkin Bio Ventures GPGP Ltd.	0001858707	Apr-29-2021	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Werewolf Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-24-196476 (33 Act) Size: KB	Aug-08-2024	333-270764 241186047
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001785530-24-000028 (34 Act) Size: KB	Aug-08-2024	001-40366 241186013
8-K	Document	Current report filing Acc-no: 0001785530-24-000026 (34 Act) Size: KB	Aug-08-2024	001-40366 241185988
8-K	Document	Current report filing Acc-no: 0001193125-24-167467 (34 Act) Size: KB	Jun-25-2024	001-40366 241066149
8-K	Document	Current report filing Acc-no: 0001193125-24-152380 (34 Act) Size: KB	Jun-03-2024	001-40366 241012013
8-K	Document	Current report filing Acc-no: 0001193125-24-148114 (34 Act) Size: KB	May-28-2024	001-40366 24992281
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001415889-24-014591 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064848 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064845 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064843 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064836 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064834 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064833 ( Act) Size: 0 KB	May-24-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-064829 ( Act) Size: 0 KB	May-24-2024
SC 13D/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001104659-24-058078 (34 Act) Size: KB	May-07-2024	005-92515 24922883
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001785530-24-000020 (34 Act) Size: KB	May-03-2024	001-40366 24910775
8-K	Document	Current report filing Acc-no: 0001785530-24-000018 (34 Act) Size: KB	May-03-2024	001-40366 24910769
ARS	Document	Annual report to security holders Acc-no: 0001140361-24-019506 (34 Act) Size: KB	Apr-12-2024	001-40366 24839970
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001140361-24-019505 (34 Act) Size: KB	Apr-12-2024	001-40366 24839968
DEF 14A	Document	Definitive proxy statements Acc-no: 0001140361-24-019504 (34 Act) Size: KB	Apr-12-2024	001-40366 24839967

Recent 20 filings. View all Werewolf Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Werewolf Therapeutics, Inc. overview
Werewolf Therapeutics, Inc. job
Werewolf Therapeutics, Inc. stock
Werewolf Therapeutics, Inc. ownership
Werewolf Therapeutics, Inc. CEO
Werewolf Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.